Vineesha Arelli, MD
Pulmonary Disease · Nashville, TNNPI 1255598363
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,750 of the $34,167 with a category attached, or 81.2%. AstraZeneca accounts for 86.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $20,865 and has fallen 73.7% since, to $5,486 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $124.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Boston Scientific$993
- GSK$633
- Boehringer Ingelheim$445
- Insmed, Inc.$401
- Regeneron Healthcare Solutions, Inc.$388
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$27,75081%
- Travel & lodging$9093%
- Food & beverage$5,24115%
- Education$2661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $29,622 |
| Boston Scientific | 11 | $993 |
| GSK | 42 | $633 |
| Boehringer Ingelheim | 18 | $445 |
| Insmed, Inc. | 18 | $401 |
| Regeneron Healthcare Solutions, Inc. | 30 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $272 |
| Sanofi | 12 | $260 |
| Actelion Pharmaceuticals US, Inc. | 7 | $174 |
| Grifols USA, LLC | 7 | $162 |
| Mylan Specialty L.p. | 8 | $136 |
| Genentech USA, Inc. | 6 | $109 |
| Harmony Biosciences LLC | 4 | $108 |
| Sunovion Pharmaceuticals Inc. | 7 | $84 |
| Novartis | 3 | $52 |
| Electromed, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Nuwellis, Inc. | 1 | $40 |
| Baxter Healthcare | 2 | $36 |
| La Jolla Pharmaceutical Company | 1 | $23 |
| Pulmonx Corporation | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Vapotherm Inc | 1 | $19 |
| Amgen | 1 | $18 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,167 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 53 | $682,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $150,080 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 184 | $144,833 |
| Fasenra PenBenralizumab | 22 | $122,261 |
| Dupixent PenDupilumab | 11 | $76,312 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $42,436 |
| Spiriva RespimatTiotropium Bromide | 28 | $25,870 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $15,993 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $10,407 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,876 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,472 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $6,152 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 235 | $5,616 |
| Roflumilast | 30 | $3,466 |
| Montelukast Sodium | 130 | $1,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $445 | $718,51199 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $633 | $173,546249 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $29,622 | $152,709205 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $272 | $42,43612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Karl KuhnNashville$106K
- Fabien MaldonadoNashville$83K
- Margaret SalisburyNashville$53K
- Victor KhaNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.